UK: NICE Wins Argument Over Appraisal Of BioMarin Rare Disease Drug
BioMarin To Re-Engage With Process But Is Doubtful Of Outcome
A decision by England’s High Court to reject claims that HTA body NICE acted unlawfully when evaluating BioMarin’s PKU treatment has quashed hopes that NICE’s Highly Specialized Technologies program will become more widely used to evaluate rare disease treatments. Lawyers representing a PKU patient are planning to appeal the judgement.
You may also be interested in...
A judicial review of how health technology appraisal body NICE decided which appraisal route BioMarin’s rare disease drug Kuvan would take could have lasting implications for future treatments.
Industry access to real world data for regulatory and market access purposes in Asia Pacific compares poorly with the US.
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.